Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment

M. G. Kris, Richard J. Gralla, L. A. Kalman, D. P. Kelsen, E. S. Casper, M. T. Burke, S. Groshen, I. R. Cibas, R. Bagin, R. T. Heelan

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

One hundred eight patients with stage III non-small cell lung cancer were randomly assigned to receive cisplatin (120 mg/m2) with either vindesine (3 mg/m2) or vinblastine (6 mg/m2). None had previously received chemotherapy. An additional goal was to determine if the observation of visible evluable lesions was as accurate a method of response assessment as the observation of bidimensionally measurable lesions in non-small cell lung cancer. When vindesine plus cisplatin was compared to vinblastine plus cisplatin, response rates (33% vs 41%), median response durations (8.6 vs 5.6 months), and median survival times of responding patients (18.4 vs 16.2 months) were similar. Response rates, response durations, and survival times of responding patients determined through the observation of evaluable or measurable indicator lesions did not differ significantly. More patients receiving vinblastine plus cisplatin experienced wbc counts < 2100/mm3 (P = 0.003). The two regimens demonstrated comparable response and survival data but clinically significant leukopenia was more common in vinblastine-treated patients. There was no difference in response data obtained through the study of patients with measurable and evaluable indicator lesions.

Original languageEnglish (US)
Pages (from-to)387-395
Number of pages9
JournalCancer Treatment Reports
Volume69
Issue number4
StatePublished - 1985
Externally publishedYes

Fingerprint

Vindesine
Vinblastine
Non-Small Cell Lung Carcinoma
Cisplatin
Observation
Survival
Leukopenia
Drug Therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment. / Kris, M. G.; Gralla, Richard J.; Kalman, L. A.; Kelsen, D. P.; Casper, E. S.; Burke, M. T.; Groshen, S.; Cibas, I. R.; Bagin, R.; Heelan, R. T.

In: Cancer Treatment Reports, Vol. 69, No. 4, 1985, p. 387-395.

Research output: Contribution to journalArticle

Kris, M. G. ; Gralla, Richard J. ; Kalman, L. A. ; Kelsen, D. P. ; Casper, E. S. ; Burke, M. T. ; Groshen, S. ; Cibas, I. R. ; Bagin, R. ; Heelan, R. T. / Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment. In: Cancer Treatment Reports. 1985 ; Vol. 69, No. 4. pp. 387-395.
@article{d68187fedc754132b5956ff1fb7eb008,
title = "Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment",
abstract = "One hundred eight patients with stage III non-small cell lung cancer were randomly assigned to receive cisplatin (120 mg/m2) with either vindesine (3 mg/m2) or vinblastine (6 mg/m2). None had previously received chemotherapy. An additional goal was to determine if the observation of visible evluable lesions was as accurate a method of response assessment as the observation of bidimensionally measurable lesions in non-small cell lung cancer. When vindesine plus cisplatin was compared to vinblastine plus cisplatin, response rates (33{\%} vs 41{\%}), median response durations (8.6 vs 5.6 months), and median survival times of responding patients (18.4 vs 16.2 months) were similar. Response rates, response durations, and survival times of responding patients determined through the observation of evaluable or measurable indicator lesions did not differ significantly. More patients receiving vinblastine plus cisplatin experienced wbc counts < 2100/mm3 (P = 0.003). The two regimens demonstrated comparable response and survival data but clinically significant leukopenia was more common in vinblastine-treated patients. There was no difference in response data obtained through the study of patients with measurable and evaluable indicator lesions.",
author = "Kris, {M. G.} and Gralla, {Richard J.} and Kalman, {L. A.} and Kelsen, {D. P.} and Casper, {E. S.} and Burke, {M. T.} and S. Groshen and Cibas, {I. R.} and R. Bagin and Heelan, {R. T.}",
year = "1985",
language = "English (US)",
volume = "69",
pages = "387--395",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment

AU - Kris, M. G.

AU - Gralla, Richard J.

AU - Kalman, L. A.

AU - Kelsen, D. P.

AU - Casper, E. S.

AU - Burke, M. T.

AU - Groshen, S.

AU - Cibas, I. R.

AU - Bagin, R.

AU - Heelan, R. T.

PY - 1985

Y1 - 1985

N2 - One hundred eight patients with stage III non-small cell lung cancer were randomly assigned to receive cisplatin (120 mg/m2) with either vindesine (3 mg/m2) or vinblastine (6 mg/m2). None had previously received chemotherapy. An additional goal was to determine if the observation of visible evluable lesions was as accurate a method of response assessment as the observation of bidimensionally measurable lesions in non-small cell lung cancer. When vindesine plus cisplatin was compared to vinblastine plus cisplatin, response rates (33% vs 41%), median response durations (8.6 vs 5.6 months), and median survival times of responding patients (18.4 vs 16.2 months) were similar. Response rates, response durations, and survival times of responding patients determined through the observation of evaluable or measurable indicator lesions did not differ significantly. More patients receiving vinblastine plus cisplatin experienced wbc counts < 2100/mm3 (P = 0.003). The two regimens demonstrated comparable response and survival data but clinically significant leukopenia was more common in vinblastine-treated patients. There was no difference in response data obtained through the study of patients with measurable and evaluable indicator lesions.

AB - One hundred eight patients with stage III non-small cell lung cancer were randomly assigned to receive cisplatin (120 mg/m2) with either vindesine (3 mg/m2) or vinblastine (6 mg/m2). None had previously received chemotherapy. An additional goal was to determine if the observation of visible evluable lesions was as accurate a method of response assessment as the observation of bidimensionally measurable lesions in non-small cell lung cancer. When vindesine plus cisplatin was compared to vinblastine plus cisplatin, response rates (33% vs 41%), median response durations (8.6 vs 5.6 months), and median survival times of responding patients (18.4 vs 16.2 months) were similar. Response rates, response durations, and survival times of responding patients determined through the observation of evaluable or measurable indicator lesions did not differ significantly. More patients receiving vinblastine plus cisplatin experienced wbc counts < 2100/mm3 (P = 0.003). The two regimens demonstrated comparable response and survival data but clinically significant leukopenia was more common in vinblastine-treated patients. There was no difference in response data obtained through the study of patients with measurable and evaluable indicator lesions.

UR - http://www.scopus.com/inward/record.url?scp=0021948856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021948856&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 387

EP - 395

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 4

ER -